Novel microglial markers that are specifically increased in early clinical AD stages
In conclusion, we identify varying microglial protein signatures spanning the AD stages, which may provide a basis for early-staging biomarkers. Independent cohort and cross-method validations are ongoing, and are necessary for the understanding of the hypothesized dynamicity of AD inflammation driven by microglia.
Authors
- Lisa Vermunt (ORCID: https://orcid.org/0000-0001-7420-6384)
- Pieter van Bokhoven (ORCID: https://orcid.org/0000-0002-8218-9921)
- Wiesje M. van der Flier (ORCID: https://orcid.org/0000-0001-8766-6224)
- Marta del Campo (ORCID: https://orcid.org/0000-0003-2808-3699)
- Walter Boiten (ORCID: https://orcid.org/0000-0001-9060-6222)
- Elena R. Blujdea (ORCID: https://orcid.org/0009-0001-7305-2122)
- Alice Chen‐Plotkin (ORCID: https://orcid.org/0000-0002-3387-2038)
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- David J. Irwin (ORCID: https://orcid.org/0000-0002-5599-5098)
- Yolande A.L. Pijnenburg (ORCID: https://orcid.org/0000-0003-2464-1905)
Institutions
- Pasqual Maragall Foundation (ES)
- Amsterdam Neuroscience (NL)
- Barcelonaβeta Brain Research Center (ES)
- Amsterdam University Medical Centers (NL)
- University of Pennsylvania (US)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.090758
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00